Type 2 diabetes affects the structure of the heart in heart failure patients and increases their risk for repeat hospitalizations and/or death, according to new research published in the Journal of the American Heart Association, the open-access journal of the American Heart Association/American Stroke Association.

Type 2 diabetes frequently coexists with heart failure, and the prevalence of diabetes has increased worldwide. While diabetes and heart failure together have been extensively studied among Western populations, there is less known about their collective impact among Asian populations. An international team of researchers analyzed data from more than nearly 6,200 heart failure patients participating in the ASIAN-HF Study.

The study found that having type 2 diabetes and heart failure was associated with:

• Structural abnormalities in the heart

• Poorer quality of life

• Increased risk of heart failure-related re-hospitalizations and/or death within 1 year

Researchers also noted that the overall prevalence of type 2 diabetes was high among these heart failure patients, with more than 40% having diabetes. The prevalence was highest in Singapore and Hong Kong.

“Primary prevention strategies and tailored treatment options are needed to tackle this twin scourge of diseases,” said study co-author Jonathan Yap, MBBS, MPH, consultant from the department of cardiology of the National Heart Centre Singapore. “Our findings emphasize the need for preventative public health measures at the community and primary care level. For heart failure patients who have diabetes, physicians should closely monitor and optimize their management.”

Co-authors are Wan Ting Tay, MAppStat; Tiew-Hwa Katherine Teng, MPH, PhD; Inder Anand, MD, PhD; A. Mark Richards, MD, PhD; Lieng Hsi Ling, MBBS, MD; Michael R. MacDonald, MBChB; Chanchal Chandramouli, PhD; Jasper Tromp, MD, PhD; Bambang B. Siswanto, MD, PhD; Michael Zile, MD, PhD; John McMurray, MBChB (Hons) MD; and Carolyn S. P. Lam, MBBS, PhD.

Author disclosures are on the manuscript. The ASIAN-HF study is supported by grants from National Medical Research Council (NMRC) Singapore; Agency for Science, Technology and Research (A*STAR) Biomedical Research Council’s Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT) program; Boston Scientific Investigator Sponsored Research Program; and Bayer.